Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

INSANE: 4 - The Real Truth

Vertex 2024 speaker: learn new art skills from creature designer Brynn Metheney

The Ghostbusters concept artist will be at Vertex 2024.

Creative Bloq · Feb 15, 2024

Why Investors Are Flocking to These 2 Medical Stocks

Given the growing demand for healthcare facilities, rapid integration of digital technology, and transformative biotechnology breakthroughs, the medical industry is poised for continued growth and profitability this year and beyond. Amid this, let’s find out why investors are flocking to medical stocks Vertex Pharmaceuticals (VRTX) and McKesson (MCK). Read more….

StockNews.com · Feb 9, 2024

What incentives do scientists have to study rare diseases? | Explained

Explore the cutting-edge research of three Breakthrough Prize laureates in Life Sciences, and the systemic issues that influence access to treatments for three diseases desperately looking for cures: Parkinson’s disease, cystic fibrosis, and cancer.

The Hindu · Dec 26, 2023

From analysis to the latest developments in health,
read the most diverse news in one place.

Promising new gene therapies for sickle cell are out of reach in countries where they're needed most

New gene therapies promise a cure for sickle cell disease but experts say they are out of reach in places that need them the most

The Independent UK · Dec 14, 2023

The Guardian view on cystic fibrosis treatments: a rollercoaster ride for the sick

Editorial: Patients are facing shorter lives as drug companies are demanding prices that health services here and in other countries cannot pay

The Guardian - UK · Dec 5, 2023

Vertex 2024 tickets now on sale!

VFX, game art, animation and more – grab your tickets to 2024's ultimate new event for the CG art community.

Creative Bloq · Dec 5, 2023

The world's 1st CRISPR therapy has just been approved. Here's everything you need to know

U.K. regulators have approved the use of a CRISPR therapy called Casgevy to treat two inherited blood disorders. But what is it and how does it work?

LiveScience · Nov 22, 2023

Read news from The Economist, FT, and more,
with one subscription

Vertex, the ultimate event for 2D and 3D artists, returns in 2024

The Vertex festival of digital art, VFX and animation is back in 2024.

Creative Bloq · Nov 20, 2023

Whether you're after a lightweight cordless or a sturdy upright, this is how the Shark Stratos vs. Vertex vacuum lineups compare

This is the range that takes the top spot in 2025

Homes & Gardens · Nov 16, 2023

‘Life-changing’ cystic fibrosis drugs approved for use in younger children

Campaigners welcomed the announcement by the Medicines and Healthcare Products Regulatory Agency.

The Independent UK · Nov 15, 2023

“We all loved Larry Carlton’s guitar, it was just magic… We were all looking for guitars with chunky necks, to try and get the sustain that he had”: Session legend Dean Parks reveals the secrets of his most iconic Steely Dan and Eric Clapton guitar parts

You can hear Parks on Josie, Haitian Divorce, Change the World, Rikki Don’t Lose That Number and innumerable other songs – here, the guitarist unpacks the gear and recording sessions that forged them

Guitar World · Aug 28, 2023

Best military watches for no-nonsense aesthetics, durability and practicality

Whether you’re a soldier or a civvie, these timepieces are built for any situation

Evening Standard · Jul 19, 2023

A Middle Age Woman Copes With Cystic Fibrosis As She Prays For A Miracle

Vertexs has been present in South Africa as the young patient copes with the high cost of the medication.

Zenger · May 15, 2023

Decentralized exchange Vertex launches on Arbitrum with backing from Jane Street and Hudson River Trading

The new, self-custodial DEX will offer high-speed spot and derivatives trading.

Fortune · Apr 26, 2023

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com · Mar 29, 2023

3 of the Best Stocks in 1 of Wall Street's Worst-Rated Industry

After years of robust growth, the biotech industry has struggled since last year due to several headwinds, including regulatory concerns, inflation, and the Fed’s aggressive rate hikes, which have sucked out speculative capital. Despite currently being one of the poorly-rated industries, investors could consider buying top-biotech stocks Gilead (GILD), Vertex…

StockNews.com · Jan 17, 2023

The No. 1 Biotech Stock to Buy for 2023

Biotech stock Vertex Pharmaceuticals (VRTX) outperformed its industry peers, gaining more than 30% over the past year. The company reported solid performance in the CF business and across the company in the last quarter. Moreover, VRTX is committed to delivering a diversified pipeline of transformative medicines and therapies. Hence, this…

StockNews.com · Nov 5, 2022

3 Stocks to Buy With Rising Recession and Rate Risk

The stock market continues to be a challenging environment with rising rates a potent headwind. So far, the economy has been stable enough so that earnings growth has not contracted, but this is unlikely to persist the longer the Fed stays hawkish. This article discusses characteristics of stocks that are…

StockNews.com · Oct 6, 2022

3 Stocks to Ride the Bear Market Rally

Stocks could be embarking on another bear market rally despite a plethora of challenges. One factor is we are entering a seasonally bullish period of the year. Another is the bullish technical setup following the undercut and recovery of the mid-June lows. 3 stocks that investors should consider buying to…

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com · Aug 16, 2022

This Biotech Breakout Star is Our Growth Stock of the Week

Vertex Pharmaceuticals (VRTX) is a high-quality biotech stock that is quite cheap with impressive growth prospects. Read on to find out why it’s our growth stock of the week….

StockNews.com · Aug 9, 2022

3 Stocks to Buy With Rising Recession Risk, Increasing Geopolitical Tensions

Despite the bear market rally, the market is facing serious risks due to rising recession risk and increasing geopolitical tensions. Here are 3 defensive picks to help investors outperform in this tricky environment: Lockheed Martin (LMT), Vertex Pharmaceuticals (VRTX), and Elevance Health (ELVH).

Benzinga · Jul 22, 2022

Daily Biotech Pulse: VistaGen's Anxiety Study Fails, Silverback To Merge With Firm Developing EpiPen Alternative, Setback For Liminal's Lead Asset

Here's a roundup of top developments in the biotech space over the last 24 hours:

Asharq Al-Awsat · Jul 18, 2022

CRISPR, 10 Years On: Learning to Rewrite the Code of Life

Ten years ago this week, Jennifer Doudna and her colleagues published the results of a test-tube experiment on bacterial genes. When the study came out in the journal Science on June 28, 2012, it did not make headline news. In fact, over the next few weeks, it did not make…

StockNews.com · Jul 4, 2022

4 "Strong Buy" Biotech Stocks to Add to Your Watchlist

As the Biotech industry’s role in finding cures for chronic diseases and critical conditions is expected to keep attracting investors’ attention, it could be wise to scoop up shares of the fundamentally-strong biotech companies Vertex Pharmaceuticals (VRTX), United Therapeutics (UTHR), Amgen (AMGN), and Sino Biopharmaceutical (SBHMY) because of their solid…

StockNews.com · Jun 29, 2022

VRTX is the Growth Stock of the Week

The market is in a tough place with stubbornly high inflation, a hawkish Fed, and a slowing economy. These conditions are tough for most stocks, but pharmaceuticals are an exception. One of the top companies in the space is Vertex Pharmaceuticals (VRTX). Read on to find out why it's our…

Benzinga · Jun 10, 2022

Looking Into Vertex's Return On Capital Employed

According to data from Benzinga Pro, during Q1, Vertex's (NASDAQ:VERX) reported sales totaled $114.98 million. Despite a 46.73% increase in earnings, the company posted a loss of $334.00 thousand.

1 2 3 4 5

Coverage From

People

Mangeet Kaur BounsMangeet

Jaimini DesaiJaimini Desai

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.